GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OKYO Pharma Ltd (NAS:OKYO) » Definitions » Net Issuance of Debt

OKYO Pharma (OKYO Pharma) Net Issuance of Debt : $2.00 Mil (TTM As of Mar. 2023)


View and export this data going back to 2022. Start your Free Trial

What is OKYO Pharma Net Issuance of Debt?

Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive. OKYO Pharma's net issuance of debt for the six months ended in Mar. 2023 was $2.00 Mil. Its net issuance of debt for the trailing twelve months (TTM) ended in Mar. 2023 was $2.00 Mil.


OKYO Pharma Net Issuance of Debt Historical Data

The historical data trend for OKYO Pharma's Net Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OKYO Pharma Net Issuance of Debt Chart

OKYO Pharma Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Net Issuance of Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only - -0.03 7.58 - 2.00

OKYO Pharma Semi-Annual Data
Sep13 Mar14 Sep14 Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23
Net Issuance of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 -0.02 0.02 - 2.00

OKYO Pharma Net Issuance of Debt Calculation

This is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Net Issuance of Debt for the trailing twelve months (TTM) ended in Mar. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $2.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


OKYO Pharma Net Issuance of Debt Related Terms

Thank you for viewing the detailed overview of OKYO Pharma's Net Issuance of Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


OKYO Pharma (OKYO Pharma) Business Description

Traded in Other Exchanges
Address
14/15 Conduit St, Floor 4, London, GBR, W1S 2XJ
OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions on various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.
Executives
John P Brancaccio director C/O TAMIR BIOTECHNOLOGY, INC., 11 DEER PARK DRIVE, SUITE 204, MONMOUTH JUNCTION NJ 08852
Gary S Jacob director, officer: Chief Executive Officer
Gabriele M Cerrone director, 10 percent owner, officer: Executive Chairman 265 EAST 66TH STREET, SUITE 16G, NEW YORK NY 10021
Bernard Denoyer director C/O CALLISTO PHARMACEUTICALS, INC., 420 LEXINGTON AVENUE, SUITE 1609, NEW YORK NY 10170
Willy Jules Simon director PLAYLOGIC INTERNATIONAL NV, CONCERTGEBOUWPLEIN 13, AMSTERDAM P7 1071 LL
Keeren Shah officer: Chief Financial Officer 55 PARK LANE, LONDON X0 W1K 1NA